UY27834A1 - Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. - Google Patents

Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.

Info

Publication number
UY27834A1
UY27834A1 UY27834A UY27834A UY27834A1 UY 27834 A1 UY27834 A1 UY 27834A1 UY 27834 A UY27834 A UY 27834A UY 27834 A UY27834 A UY 27834A UY 27834 A1 UY27834 A1 UY 27834A1
Authority
UY
Uruguay
Prior art keywords
piiridino
tieno
carboxylic
procedures
amino
Prior art date
Application number
UY27834A
Other languages
English (en)
Inventor
Charles L Cywin
Zhidong Chen
Jonathan Emeigh
Roman Wolfgang Fleck
Ming Hong Hao
Eugene Richard Hickey
Will Weimin Liu
Daniel R Marshall
Tina M Morwick
Mr Peter Allen Nemoto
Ronald J Sorcek
Sanxing Sun
Jiang-Ping Wu
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY27834A1 publication Critical patent/UY27834A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/695—Polyesters containing atoms other than carbon, hydrogen and oxygen containing silicon
    • C08G63/6954—Polyesters containing atoms other than carbon, hydrogen and oxygen containing silicon derived from polxycarboxylic acids and polyhydroxy compounds
    • C08G63/6956—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/916—Dicarboxylic acids and dihydroxy compounds

Abstract

Se describen compuestos de fórmula (I): en la que R1 y R2 se definen en la presente memoria descriptiva, que son útiles como inhibidores de la actividad de quinasa del complejo de IKB quinasa (IKK). Por lo tanto, los compuestos son útiles en el tratamiento de enfermedades mediadas por IKK que incluyen enfermedades inmunes, enfermedades inflamatorias y cáncer. Se describen también composiciones farmacéuticas que comprenden estos compuestos y procedimientos para preparar estos compuestos.
UY27834A 2002-06-06 2003-06-03 Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. UY27834A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38631202P 2002-06-06 2002-06-06
US45786703P 2003-03-26 2003-03-26

Publications (1)

Publication Number Publication Date
UY27834A1 true UY27834A1 (es) 2003-12-31

Family

ID=29739900

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27834A UY27834A1 (es) 2002-06-06 2003-06-03 Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.

Country Status (27)

Country Link
US (2) US6964956B2 (es)
EP (2) EP2008654A1 (es)
JP (2) JP4364120B2 (es)
KR (1) KR20050005548A (es)
CN (1) CN100386329C (es)
AR (1) AR040250A1 (es)
AT (1) ATE415966T1 (es)
AU (1) AU2003237330A1 (es)
BR (1) BR0311605A (es)
CA (1) CA2483890C (es)
DE (1) DE60325051D1 (es)
DK (1) DK1513516T3 (es)
EA (1) EA008706B1 (es)
ES (1) ES2318141T3 (es)
HK (1) HK1080737A1 (es)
HR (1) HRP20041154A2 (es)
IL (1) IL164597A0 (es)
ME (2) ME00355B (es)
MX (1) MXPA04011246A (es)
NO (1) NO20044599L (es)
NZ (1) NZ537394A (es)
PE (1) PE20040539A1 (es)
PL (1) PL373424A1 (es)
RS (1) RS105204A (es)
TW (1) TWI296927B (es)
UY (1) UY27834A1 (es)
WO (1) WO2003103661A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780785B2 (en) 2001-10-26 2010-08-24 Applied Materials, Inc. Gas delivery apparatus for atomic layer deposition
ES2318141T3 (es) 2002-06-06 2009-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de amida de acido 3-amino-tieno(2,3-b)piridina-2-carboxilico y procedimiento de preparacion y sus usos.
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
JP2007533602A (ja) * 2003-07-31 2007-11-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾチオフェン化合物及びそれらの使用
US7291733B2 (en) * 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
MXPA06005934A (es) * 2003-12-05 2006-07-06 Boehringer Ingelheim Pharma Compuestos de amida del acido 3-amino-tieno[2,3-b]piridin-2-carboxilico sustituido como inhibidores de la ikk.
CA2562827A1 (en) * 2004-04-12 2005-10-27 Sankyo Company Limited Thienopyridine derivatives
RU2006142741A (ru) * 2004-05-04 2008-06-10 Ф.Хоффманн-Ля Рош Аг (Ch) Тиенопиридины как ингибиторы ikk
RU2006142740A (ru) * 2004-05-04 2008-06-10 Ф.Хоффманн-Ля Рош Аг (Ch) Тиенопиридазины в качестве ингибиторов ikk
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
CN1997370B (zh) * 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
JP2007277093A (ja) * 2004-06-21 2007-10-25 Astellas Pharma Inc 三環系化合物
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
EP1879899B1 (en) * 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
EP1681292A1 (de) * 2005-01-12 2006-07-19 IBFB Pharma GmbH 3-Amino-6-aryl(bzw.6-heteroaryl)-thieno¬2,3-b|pyridin-2-carbonsäureamide, diese enthaltende pharmazeutische Zubereitungen und ihre Verwendung als Inhibitoren der TNFalpha-Freisetzung
EP1683799A1 (de) * 2005-01-12 2006-07-26 IBFB Pharma GmbH 3-Amino-6aryl(bzw.6-heteroaryl)-4-R²-thieno[2,3-b]pyridin-2-carbonsäureamide, diese enthaltende pharmazeutische Zubereitungen und deren Verwendung als Inhibitoren der TNFalpha-Freisetzung
WO2006074919A2 (de) * 2005-01-12 2006-07-20 Curacyte Discovery Gmbh 3 -AMINO- 6-ARYL (BZW.6-HETEROARYL) -THIENO [2 , 3-B] PYRIDIN-2-CARBONSÄUREAMIDE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER TNFα-FREISETZUNG
US7465742B2 (en) * 2005-02-11 2008-12-16 Huanming Chen Heterocyclic compounds having anti-HBV activity
EP1908480A4 (en) * 2005-06-03 2009-07-01 Riken INTERFERON-ALPHA REGULATOR
CN1884262B (zh) * 2005-06-24 2014-06-25 中国人民解放军军事医学科学院毒物药物研究所 4-氨基哌啶类化合物及其医药用途
JP5059756B2 (ja) 2005-06-30 2012-10-31 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
TW200801016A (en) * 2005-10-12 2008-01-01 Sankyo Co Thienopyridine-2-carboxamide derivatives
KR100846988B1 (ko) * 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
CA2653654A1 (en) * 2006-06-06 2007-12-21 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
US20080032409A1 (en) * 2006-08-07 2008-02-07 California Institute Of Technology Fluorescent biomolecule labeling reagents
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ［２，３−ｄ］ピリミジン化合物
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CN101684123B (zh) * 2008-09-27 2013-12-11 四川大学 2-甲酰胺基噻吩并吡啶衍生物制备方法及医药用途
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US8481547B2 (en) * 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
PL2812337T3 (pl) * 2012-02-09 2017-01-31 Merck Patent Gmbh Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
RU2557550C1 (ru) * 2014-06-16 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Антидот гербицида 2,4-дихлорфеноксиуксусной кислоты на подсолнечнике
CA2988421A1 (en) * 2015-06-01 2016-12-08 The Scripps Research Institute Small molecule analogs of the nemo binding peptide
AU2016348659B2 (en) * 2015-11-03 2022-07-28 Lu License Ab Compounds for treatment of hypoproliferative disorders
TWI753910B (zh) * 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
CN112638382A (zh) * 2018-06-06 2021-04-09 国家医疗保健研究所 作为epac抑制剂的噻吩并[2，3-b]吡啶衍生物及其药物用途
US11014906B2 (en) 2018-08-21 2021-05-25 University Of South Carolina Quinoline-based compounds and methods of inhibiting CDK8/19
EP3917523A4 (en) 2019-02-01 2022-10-19 University of South Carolina BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USE THERE FOR CANCER THERAPY
WO2020237014A1 (en) * 2019-05-21 2020-11-26 University Of South Carolina 3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same
CN113248353B (zh) * 2021-07-01 2022-02-25 山东国邦药业有限公司 一种2,4-二氯-5-氟苯乙酮的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50140487A (es) * 1974-04-15 1975-11-11
WO1992003427A1 (en) 1990-08-17 1992-03-05 Yoshitomi Pharmaceutical Industries, Ltd. Ketone compound and remedy for osteoporosis
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
JP3254843B2 (ja) * 1993-08-09 2002-02-12 三菱ウェルファーマ株式会社 新規縮合ヘテロ環誘導体
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4420922A1 (de) 1994-06-16 1995-12-21 Bayer Ag Verfahren zur Herstellung von Benzothiophenderivaten
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US6313301B1 (en) * 1997-08-13 2001-11-06 Takeda Chemical Industries, Ltd. Thienopyridine derivatives, their intermediates and production thereof
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ES2219033T3 (es) * 1998-07-22 2004-11-16 Daiichi Suntory Pharma Co., Ltd. Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo.
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
RS50340B (sr) 1999-06-23 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Supstituisani benzimidazoli
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
AU2001252463A1 (en) * 2000-06-06 2001-12-17 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
AU2002239806B2 (en) 2000-10-26 2007-01-18 Amgen Inc. Antiinflammation agents
EP1417315A2 (en) 2001-07-20 2004-05-12 Emerald Bioagriculture Corporation Plant ion channels and methods
CA2464924A1 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
ES2318141T3 (es) 2002-06-06 2009-05-01 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos de amida de acido 3-amino-tieno(2,3-b)piridina-2-carboxilico y procedimiento de preparacion y sus usos.
US6974870B2 (en) 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
WO2005001849A1 (fr) 2003-06-27 2005-01-06 Eremeev, Petr Igorevich Procede de prise en charge du combustible nucleaire epuise
JP2007533602A (ja) 2003-07-31 2007-11-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾチオフェン化合物及びそれらの使用
US7291733B2 (en) 2003-10-10 2007-11-06 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted tricyclic heterocycles and their uses
MXPA06005934A (es) 2003-12-05 2006-07-06 Boehringer Ingelheim Pharma Compuestos de amida del acido 3-amino-tieno[2,3-b]piridin-2-carboxilico sustituido como inhibidores de la ikk.
JP2005194198A (ja) 2003-12-26 2005-07-21 Takeda Chem Ind Ltd チエノピリジン化合物
WO2006019832A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1805187A1 (en) 2004-10-21 2007-07-11 Pfizer, Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
US20060293709A1 (en) 2005-06-24 2006-12-28 Bojarski Raymond A Tissue repair device

Also Published As

Publication number Publication date
NZ537394A (en) 2006-12-22
EP2008654A1 (en) 2008-12-31
ME00355B (me) 2010-06-30
EP1513516A1 (en) 2005-03-16
EA200401541A1 (ru) 2005-06-30
WO2003103661A1 (en) 2003-12-18
PL373424A1 (en) 2005-08-22
MEP53508A (en) 2011-05-10
MXPA04011246A (es) 2005-06-03
HK1080737A1 (en) 2006-05-04
CA2483890A1 (en) 2003-12-18
EP1513516B1 (en) 2008-12-03
DE60325051D1 (de) 2009-01-15
JP2009102447A (ja) 2009-05-14
ATE415966T1 (de) 2008-12-15
BR0311605A (pt) 2005-02-22
IL164597A0 (en) 2005-12-18
US20040053957A1 (en) 2004-03-18
HRP20041154A2 (en) 2005-06-30
DK1513516T3 (da) 2009-10-19
ES2318141T3 (es) 2009-05-01
AU2003237330A1 (en) 2003-12-22
PE20040539A1 (es) 2004-10-21
KR20050005548A (ko) 2005-01-13
EA008706B1 (ru) 2007-06-29
US20050288285A1 (en) 2005-12-29
CN100386329C (zh) 2008-05-07
CN1649581A (zh) 2005-08-03
JP2005530816A (ja) 2005-10-13
CA2483890C (en) 2012-12-11
RS105204A (en) 2006-12-15
NO20044599L (no) 2005-02-16
US7405225B2 (en) 2008-07-29
TW200401640A (en) 2004-02-01
US6964956B2 (en) 2005-11-15
AR040250A1 (es) 2005-03-23
TWI296927B (en) 2008-05-21
JP4364120B2 (ja) 2009-11-11

Similar Documents

Publication Publication Date Title
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
ECSP045477A (es) COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS.
CO2022016377A2 (es) Inhibidores de kras tricíclicos fusionados
BR112013012502A2 (pt) pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
PA8617701A1 (es) Nuevos compuestos farmaceuticos
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
ECSP099465A (es) Polimorfos de sal de succinato 2-[6-(3-amino-piperidin-1-ilo)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y métodos
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
ECSP055680A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
UY30282A1 (es) Compuestos quimicos
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
UY28647A1 (es) Compuestos de amida del ácido 3-amino-tieno(2,3-b)piridin-2-carboxílico sustituido y procedimientos para su preparación y sus usos
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126